论文部分内容阅读
目的:研究阿托伐他汀片在新西兰兔体内的药代动力学。方法:18只成年健康雄性新西兰兔,随机分为正常对照组、10mg/kg·d阿托伐他汀片组与15mg/kg·d阿托伐他汀片组,每组6只,采用RP-HPLC法测定血药浓度,计算药代动力学参数。结果:10mg/kg·d组与15mg/kg·d组的主要药代动力学参数分别为:AUC0～t/μg·L-1·h为(619.58±215.45)与(1138.34±422.32)、AUC0～∞/μg·L-1·h为(655.68±242.83)与(1216.57±353.64)、Cmax/μg·L-1为(455.81±168.52)和(896.53±168.5.8)、MRT0～t/h为(3.68±0.75)与(5.73±0.56)、MRT0～∞/h为(3.83±0.91)与(5.25±0.48)、Tmax/h为(2.51±0.82)与(3.68±0.33)、T1/2/h为(4.22±0.55)与(9.51±0.67)。结论:RP-HPLC法适用于阿托伐他汀片动物药代动力学的研究。
Objective: To study the pharmacokinetics of atorvastatin tablets in New Zealand rabbits. Methods: Eighteen adult healthy male New Zealand white rabbits were randomly divided into normal control group, 10 mg / kg · d atorvastatin tablet group and 15 mg / kg · d atorvastatin tablet group, Determination of plasma concentration, calculation of pharmacokinetic parameters. Results: The main pharmacokinetic parameters of 10 mg / kg · d group and 15 mg / kg · d group were AUC0 ~ t / μg · L-1 · h (619.58 ± 215.45) and (1138.34 ± 422.32) ~ (455.81 ± 168.52) and (896.53 ± 168.5.8), (Cmax / μg · L-1), MRT0 ~ t / h (3.83 ± 0.91) and (5.25 ± 0.48), Tmax / h were (2.51 ± 0.82) and (3.68 ± 0.33) and T1 / 2 / h was (4.22 ± 0.55) and (9.51 ± 0.67). Conclusion: RP-HPLC method is suitable for pharmacokinetics of atorvastatin tablets.